Clinical trials
catalyst calendar across sponsors →Studies where UPB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 2 with posted results
Held by 12 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., Qube Research & Technologies Ltd, AQR CAPITAL MANAGEMENT LLC, Point72 Asset Management, L.P., +7 more) · FINRA short interest 7.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 5 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDNCT06981078Annualized rate of moderate or severe COPD exacerbation eventsRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Verekitug · Other: Placebo | Chronic Obstructive Pulmonary Disease | 666 | Oct 2027 | ≤ 438 d | 2026-07-20 |
| A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)NCT06966479Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Verekitug, Placebo | Severe Asthma | 396 | Sep 2027 | ≤ 407 d | 2026-05-14 |
| A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)NCT06196879Annual Asthma Exacerbation Rate (AAER)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Verekitug (UPB-101), Placebo | Severe Asthma | 479 | 2025-12-16actual | — | 2026-05-01 |
| A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal PolypsNCT06164704Change From Baseline in Nasal Polyp Score (NPS) at Week 24Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Verekitug (UPB-101), Placebo | Chronic Rhinosinusitis With Nasal Polyps | 81 | 2025-07-07actual | — | 2025-08-15 |
| Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in AsthmaticsNCT05448651results2025-01-03Number of Treatment-emergent Adverse Events and Serious Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: UPB-101, Placebo | Asthma | 32 | 2023-08-15actual | — | 2025-01-03 |
| Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian AdultsNCT05653479results2024-09-03Maximum Observed Concentration (Cmax) of UPB-101Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: UPB-101 | Healthy | 32 | 2023-04-07actual | — | 2024-09-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19